% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • metropath metropath Sep 20, 2013 10:18 AM Flag

    OT: RNA

    On June 27, 2013, GSK announced that the U.S. Food and Drug Administration, or FDA, had provided notification that drisapersen has been granted Breakthrough Therapy Designation for the treatment of DMD Breakthrough Therapy Designation is an FDA program intended to facilitate and expedite development and review of new drugs to address unmet medical need in the treatment of serious or life-threatening conditions
    After 3 months, GSK announced the failure in late stage trial this morning. One example of Breakthrough Therapy Designation.

    Sentiment: Strong Buy

4.67-0.15(-3.11%)May 3 4:00 PMEDT